Results round-up: Mindray and Fresenius disappoint in Q1
This article was originally published in Clinica
Executive Summary
China’s Mindray Medical International posted a mixed first quarter, with revenues up 9% year-on-year but $27m short of analyst forecasts as it continues to see deceleration in its domestic market. Sales growth in China, which accounts for 44% of the firm’s sales, slowed to 4% in Q1, from 8% in Q4 and 17% last year, noted Jefferies analyst Raj Denhoy.